Answers are grounded in this paper and cite their sources.
Objective This study aimed to compare the demographic characteristics, laboratory parameters, major clinical complications, and comorbidities of hospitalized children with Epstein–Barr virus (EBV) infection across three calendar periods—2018–2019, 2020–2022, and 2023–2025—and to describe temporal changes in the characteristics of hospitalized cases during periods broadly overlapping with different phases of the COVID-19 pandemic. Methods The study period was divided into three calendar periods: 2018–2019, 2020–2022, and 2023–2025, which broadly overlapped with different phases of the COVID-19 pandemic. This temporal classification was used solely to describe period-specific differences in the clinical and laboratory characteristics of hospitalized children with EBV infection and was not intended to infer causal effects of the COVID-19 pandemic or related public health measures on EBV infection. The numbers of hospitalized children included in the three periods were 39, 96, and 307, respectively, resulting in marked imbalance in group sizes. Annual case numbers also varied substantially, with 4 cases in 2018, 35 in 2019, 2 in 2020, 21 in 2021, 73 in 2022, and 117, 119, and 71 cases in 2023, 2024, and 2025, respectively. Results The age distribution differed across periods (χ² = 20.07, P < 0.001), with older children accounting for a larger proportion in 2023–2025. EBV nuclear antigen antibody and viral capsid antigen IgG levels were higher in 2020–2022 than in the other periods, whereas plasma EBV-DNA levels were lower. Infection-status classification was available for 267 children, with substantial differences in data completeness across periods. Non-severe pneumonia showed a nominal period difference (P = 0.046); no statistically significant differences were detected for the other evaluated clinical outcomes. Documented coinfection occurred in 206 children (46.61%) and was associated with higher odds of non-severe pneumonia (OR = 2.63, 95% CI: 1.79–3.87) and severe pneumonia (OR = 5.23, 95% CI: 1.47–18.62), but lower odds of liver function impairment (OR = 0.31, 95% CI: 0.15–0.68). Hospitalization costs were higher in 2023–2025. Conclusion Across the three calendar periods broadly overlapping with different phases of the COVID-19 pandemic, hospitalized children with EBV infection showed temporal differences in age distribution, selected laboratory parameters, and the distribution of EBV infection status. Infection-status analysis indicated a lower proportion of acute primary infection in 2020–2022 than in 2023–2025; however, this finding should be interpreted cautiously because of differences in the completeness of infection-status classification across periods. These findings reflect period-specific characteristics of hospitalized children and should not be interpreted as evidence of changes in EBV epidemiology in the general pediatric population.
No takes yet. Share an insight, caveat, or question.
Zhang¹⁺, et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: